Avitinib - Hangzhou ACEA Pharmaceutical Research

Drug Profile

Avitinib - Hangzhou ACEA Pharmaceutical Research

Alternative Names: AC0010; Avitinib maleate

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hangzhou ACEA Pharmaceutical Research
  • Developer Hangzhou ACEA Pharmaceutical Research; Sun Yat-Sen University
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 18 May 2017 Phase-II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT03300115)
  • 07 Apr 2017 Phase-I/II development for Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) is ongoing in China (PO)
  • 06 Mar 2017 Adverse events and efficacy data from a phase I/II trial in Non-small cell lung cancer presented at the 15th International Congress on Targeted Anticancer Therapies (TAT-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top